Capsugel Opens QC Lab
Capsugel has opened its new quality control lab in Greenwood, SC, doubling its lab capacity and investing more than $3 million.
Capsugel has opened its new quality control lab in Greenwood, SC, doubling its lab capacity and investing more than $3 million. The new lab serves as a global resource to its network of manufacturing sites and R&D labs in Boston, Strasbourg and Colmar. The facility provides quality control and all raw materials and specialty testing of finished products.
The 9,600-sq.-ft. facility is equipped to provide a range of analytical and microbial testing, as well as development of color formulations. The company has expanded its global stability program with walk-in stability chambers and photo stability chambers to support the shelf life of the finished products, to register new products in different countries, and to conduct excursion studies to determine temperature and humidity conditions on the quality of the capsules.
“Our new Quality Control Laboratory positions Capsugel for future growth in an increasingly complex regulatory marketplace,” said Guido Driesen, president and chief executive officer of Capsugel. “Quality is the hallmark of our business and a core principle at Capsugel that provides added value to our customers. Our thorough testing equates to faster time to market as our products are designed to comply with today’s strict regulations.”
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.